Aghaloo, T.L., Cheong, S., Bezouglaia, O., Kostenuik, P., Atti, E., Dry, S.M., et al. RANKL inhibitors induce osteonecrosis of the jaw in mice with periapical disease. J Bone Miner Res 29 (2014), 843–854.
Aghaloo, T.L., Kang, B., Sung, E.C., Shoff, M., Ronconi, M., Gotcher, J.E., et al. Periodontal disease and bisphosphonates induce osteonecrosis of the jaws in the rat. J Bone Miner Res 26 (2011), 1871–1882.
Aguirre, J.I., Akhter, M.P., Kimmel, D.B., Pingel, J.E., Williams, A., Jorgensen, M., et al. Oncologic doses of zoledronic acid induce osteonecrosis of the jaw-like lesions in rice rats (Oryzomys palustris) with periodontitis. J Bone Miner Res 27 (2012), 2130–2143.
Berti-Couto, S.A., Vasconcelos, A.C., Iglesias, J.E., Figueiredo, M.A., Salum, F.G., Cherubini, K., Diabetes mellitus and corticotherapy as risk factors for alendronate-related osteonecrosis of the jaws: a study in Wistar rats. Head Neck 36 (2014), 84–93.
Bezzi, M., Hasmim, M., Bieler, G., Dormond, O., Ruegg, C., Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt. J Biol Chem 278 (2003), 43603–43614.
Boonyapakorn, T., Schirmer, I., Reichart, P.A., Sturm, I., Massenkeil, G., Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 44 (2008), 857–869.
Conte Neto, N., Spolidorio, L.C., Andrade, C.R., A SB, Guimaraes, M., Marcantonio, E. Jr., Experimental development of bisphosphonate-related osteonecrosis of the jaws in rodents. Int J Exp Pathol 94 (2013), 65–73.
de Molon, R.S., Cheong, S., Bezouglaia, O., Dry, S.M., Pirih, F., Cirelli, J.A., et al. Spontaneous osteonecrosis of the jaws in the maxilla of mice on antiresorptive treatment: a novel ONJ mouse model. Bone 68 (2014), 11–19.
Dimopoulos, M.A., Kastritis, E., Bamia, C., Melakopoulos, I., Gika, D., Roussou, M., et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 20 (2009), 117–120.
Ficarra, G., Beninati, F., Rubino, I., Vannucchi, A., Longo, G., Tonelli, P., et al. Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment. J Clin Periodontol 32 (2005), 1123–1128.
Gaudin, E., Seidel, L., Bacevic, M., Rompen, E., Lambert, F., Occurrence and risk indicators of medication-related osteonecrosis of the jaw after dental extraction: a systematic review and meta-analysis. J Clin Periodontol 42 (2015), 922–932.
Hoff, A.O., Toth, B.B., Altundag, K., Johnson, M.M., Warneke, C.L., Hu, M., et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23 (2008), 826–836.
Hokugo, A., Christensen, R., Chung, E.M., Sung, E.C., Felsenfeld, A.L., Sayre, J.W., et al. Increased prevalence of bisphosphonate-related osteonecrosis of the jaw with vitamin D deficiency in rats. J Bone Miner Res 25 (2010), 1337–1349.
Kang, B., Cheong, S., Chaichanasakul, T., Bezouglaia, O., Atti, E., Dry, S.M., et al. Periapical disease and bisphosphonates induce osteonecrosis of the jaws in mice. J Bone Miner Res 28 (2013), 1631–1640.
Lopez-Jornet, P., Camacho-Alonso, F., Molina-Minano, F., Gomez-Garcia, F., Vicente-Ortega, V., An experimental study of bisphosphonate-induced jaws osteonecrosis in Sprague-Dawley rats. J Oral Pathol Med 39 (2010), 697–702.
Marx, R., Oral and intravenous biphosphonate induced osteonecrosis of the jaws: history, etiology, prevention, and treatment. 2011, Quintessence Publishing, Hanover Park.
Marx, R.E., Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61 (2003), 1115–1117.
Mawardi, H., Giro, G., Kajiya, M., Ohta, K., Almazrooa, S., Alshwaimi, E., et al. A role of oral bacteria in bisphosphonate-induced osteonecrosis of the jaw. J Dent Res 90 (2011), 1339–1345.
Moreira, M.M., Bradaschia-Correa, V., Marques, N.D., Ferreira, L.B., Arana-Chavez, V.E., Ultrastructural and immunohistochemical study of the effect of sodium alendronate in the progression of experimental periodontitis in rats. Microsc Res Tech 77 (2014), 902–909.
Otto, S., Pautke, C., Martin Jurado, O., Nehrbass, D., Stoddart, M.J., Ehrenfeld, M., et al. Further development of the MRONJ minipig large animal model. J Craniomaxillofac Surg 45 (2017), 1503–1514.
Otto, S., Pautke, C., Opelz, C., Westphal, I., Drosse, I., Schwager, J., et al. Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism. J Oral Maxillofac Surg 68 (2010), 2837–2845.
Otto, S., Schreyer, C., Hafner, S., Mast, G., Ehrenfeld, M., Sturzenbaum, S., et al. Bisphosphonate-related osteonecrosis of the jaws─characteristics, risk factors, clinical features, localization and impact on oncological treatment. J Craniomaxillofac Surg 40 (2012), 303–309.
Otto, S., Troltzsch, M., Jambrovic, V., Panya, S., Probst, F., Ristow, O., et al. Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: a trigger for BRONJ development?. J Craniomaxillofac Surg 43 (2015), 847–854.
Park, S., Kanayama, K., Kaur, K., Tseng, H.C., Banankhah, S., Quje, D.T., et al. Osteonecrosis of the Jaw Developed in Mice: disease variants regulated by gammadelta T cells in oral mucosal barrier immunity. J Biol Chem 290 (2015), 17349–17366.
Ripamonti, C.I., Maniezzo, M., Campa, T., Fagnoni, E., Brunelli, C., Saibene, G., et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 20 (2009), 137–145.
Ruggiero, S.L., Dodson, T.B., Assael, L.A., Landesberg, R., Marx, R.E., Mehrotra, B., Task force on bisphosphonate-related osteonecrosis of the jaws, American association of oral and maxillofacial Surgeons: American association of oral and maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update. Aust Endod J 35 (2009), 119–130.
Ruggiero, S.L., Dodson, T.B., Fantasia, J., Goodday, R., Aghaloo, T., Mehrotra, B., et al. American association of oral and maxillofacial surgeons: American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw─2014 update. J Oral Maxillofac Surg 72 (2014), 1938–1956.
Russell, R.G., Watts, N.B., Ebetino, F.H., Rogers, M.J., Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19 (2008), 733–759.
Saad, F., Brown, J.E., Van Poznak, C., Ibrahim, T., Stemmer, S.M., Stopeck, A.T., et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 23 (2012), 1341–1347.
Saia, G., Blandamura, S., Bettini, G., Tronchet, A., Totola, A., Bedogni, G., et al. Occurrence of bisphosphonate-related osteonecrosis of the jaw after surgical tooth extraction. J Oral Maxillofac Surg 68 (2010), 797–804.
Sakaguchi, O., Kokuryo, S., Tsurushima, H., Tanaka, J., Habu, M., Uehara, M., et al. Lipopolysaccharide aggravates bisphosphonate-induced osteonecrosis in rats. Int J Oral Maxillofac Surg 44 (2015), 528–534.
Sharma, D., Hamlet, S., Petcu, E., Ivanovski, S., Animal models for bisphosphonate-related osteonecrosis of the jaws─an appraisal. Oral Dis 19 (2013), 747–754.
Tsao, C., Darby, I., Ebeling, P.R., Walsh, K., O'Brien-Simpson, N., Reynolds, E., et al. Oral health risk factors for bisphosphonate-associated jaw osteonecrosis. J Oral Maxillofac Surg 71 (2013), 1360–1366.
Tsurushima, H., Kokuryo, S., Sakaguchi, O., Tanaka, J., Tominaga, K., Bacterial promotion of bisphosphonate-induced osteonecrosis in Wistar rats. Int J Oral Maxillofac Surg 42 (2013), 1481–1487.
Williams, D.W., Lee, C., Kim, T., Yagita, H., Wu, H., Park, S., et al. Impaired bone resorption and woven bone formation are associated with development of osteonecrosis of the jaw-like lesions by bisphosphonate and anti-receptor activator of NF-kappaB ligand antibody in mice. Am J Pathol 184 (2014), 3084–3093.
Wood, J., Bonjean, K., Ruetz, S., Bellahcene, A., Devy, L., Foidart, J.M., et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302 (2002), 1055–1061.
